Although completed clinical trial visits are 37 percent below pre-COVID-19 levels, scheduled visits rose by the end of May to almost 20 percent above the COVID-19 low of late April, according to a COVID-19 Benchmark Data survey published last week by Bio-Optronics.
The survey also found that sites’ patient communication at the end of May was 20 percent above pre-COVID-19 levels. This likely comes from sites use of text messaging and telemedicine to communicate with patients.
Since April 12, per-week enrollment activity in clinical trials has increased by 38 percent. The survey also reported a 17 percent increase in community interest of studies displayed on site websites from late April to the end of May. Also, the survey found that sites are adding more studies, with this activity in May 2020 falling only 4 percent below pre-pandemic levels.
The survey was conducted of 1,275 sites and 30,000 users of Bio-Optronics’ software.